CD8A and neoplasm: While anti-CTLA-4 eliminates the inhibition of CD4+ T cell activity in the lymph nodes, anti-PD-L1 is directed against the blockage of the CD8+ T cells in the tumor and in the peritumoral tissue [11,12].